Description of possible side effects of Anamorelin

Anamorelin (Anamorelin), as an oral growth hormone secretory peptide receptor agonist, can act on the appetite center of the brain by activating the GHS-R1a receptor, thereby improving appetite and weight in patients with cancer cachexia. However, although the drug has shown potential to improve body weight and nutritional status in clinical trials, its side effects still require careful attention.

The most common adverse reactions are mainly in the metabolic and digestive systems. Some patients may experience an increase in blood sugar while taking the drug. This is because GHS-R1a receptor activation can indirectly affect insulin secretion and glucose metabolism. For patients with existing diabetes or poor blood sugar control, blood sugar levels need to be monitored regularly during the use of anamorelin, and medication or dietary management should be adjusted according to the clinical situation.

In addition, water and sodium retention may cause mild to moderate edema, manifesting as swelling of the hands, feet, or face. This condition can usually be alleviated by dose adjustment or symptomatic management, but extreme caution is required in patients with cardiac dysfunction to avoid heart failure or exacerbation of the preexisting cardiac burden. Some patients may also experience mild gastrointestinal symptoms such as bloating, nausea, diarrhea, or constipation, which are related to the drug's effect on the smooth muscle of the gastrointestinal tract and the rate of gastric emptying.

Regarding the cardiovascular system, a small number of patients in clinical trials experienced increased heart rate or mild arrhythmia, especially those with underlying heart disease or those taking other stimulant drugs at the same time. Although most symptoms are tolerable, patients at high risk should undergo ECG monitoring. Other rare but concerning adverse reactions include headache, fatigue, muscle pain, and blood pressure fluctuations, which mostly resolve after dose adjustment or discontinuation of the drug.

In general, the side effects of anamorelin are generally controllable, but patients should closely monitor blood sugar, weight changes, edema, and cardiovascular indicators during use. Clinicians should develop individualized management plans based on the patient's underlying disease, drug tolerance, and combined medication to ensure both efficacy and safety.

Reference materials:https://pmc.ncbi.nlm.nih.gov/articles/PMC4677053/